BERKELEY, CA (UroToday.com) - Since the introduction of targeted therapy for the treatment of advanced renal cell carcinoma (RCC) the prognosis of this condition has improved.
Six targeted agents (sorafenib, sunitinib, bevacizumab plus interferon (IFN), temsirolimus, pazopanib and everolimus) have now been approved for the treatment of RCC, and others will soon join the market. Although these treatments rarely result in a complete disease response, they do offer the possibility of stabilizing disease over a long period of time. Strategies that have been proposed for improving the overall duration of response to targeted therapy include combination therapy, dose escalation and using the available treatments in sequence...View or save the full text Mini Review as a .pdf file
Ziya Kirkali
Dokuz Eylul University, School of Medicine, Izmir, Turkey
More BJUI Mini Reviews and Archives
